Iksuda Therapeutics closes $47m financing round
Funding to accelerate clinical progression of Iksuda’s pipeline of new generation of antibody drug conjugates, targeting tumours with high unmet need.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1997 entries already.
Entries by Thomas Gabrielczyk
International control of hemp and cannabinoids
For a plant that has been used for millennia, controls on the supply of psychoactive and non-psychoactive components extracted from cannabis are relatively recent, with global regulations starting in the 20th century with the International Opium Conventions. The current, and often conflicting, regulatory landscape has focused on definitions of hemp and cannabidiol (CBD). Reference materials are critical to defining the % ?9-THC in these products.
B Medical Systems’ reliable ultra-low freezers
Ultra-low freezers, or ULTs, are specialised refrige-rating equipment created to store vaccines, medicines, and samples at ultra-low temperatures. By offering storage temperatures ranging from -20°C to -86°C and energy efficiency, B Medical Systems ULTs create an ideal environment for the long-term storage of extremely temperature-sensitive biologicals, making its products perfect for use in laboratory or clinical environments.
Lonza expands EU production capacity for Moderna vaccine
Lonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
EU approves Biontech/Pfizer vaccine for adolescents
The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Bio and Bluerock ink Regmed collaboration
Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.
Pieris in $1.4bn deal with Roche
German-US Anticalin specialist Pieris Pharmaceuticals has bagged $20m upfront for a strategic R&D and license agreement with Genentech, the US branch of Swiss Roche AG.
|
|
|
||
Associations call for acceleration of ATMP trials in Europe
Life science associations are calling for ATMPs to be exempted from the strict EU GMO rules, as their different legal interpretations in EU member states are delaying applications for multicentre clinical trials.
Red blood cell contaminants from source material
Isolating cells from whole blood or LRS cones carries the risk of red blood cell (RBC) contamination, which can have deleterious effects on downstream cell cultures.
AAV Gene Therapy: Monitoring Manufacturing
Adeno-associated viruses (AAV) have revolutionised gene therapies as safe and effective gene shuttles. The growing demand for AAV vectors now requires an industrialised process throughout pre-clinical development that involves comprehensive monitoring from production to patient to ensure safety and efficacy of the therapeutic agent and reduce cost of goods.